| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1094 | 2019 |
| Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses Y Lavin, S Kobayashi, A Leader, ED Amir, N Elefant, C Bigenwald, ... Cell 169 (4), 750-765. e17, 2017 | 1055 | 2017 |
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ... The Lancet Oncology 19 (5), 694-704, 2018 | 366 | 2018 |
| T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma AC Hopkins, M Yarchoan, JN Durham, EC Yusko, JA Rytlewski, ... JCI insight 3 (13), 2018 | 217 | 2018 |
| Correction of aberrant growth preserves tissue homeostasis S Brown, CM Pineda, T Xin, J Boucher, KC Suozzi, S Park, ... Nature 548 (7667), 334-337, 2017 | 148 | 2017 |
| TGF-β-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma JA Brown, Y Yonekubo, N Hanson, A Sastre-Perona, A Basin, ... Cell stem cell 21 (5), 650-664. e8, 2017 | 146 | 2017 |
| The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity S Palakurthi, M Kuraguchi, SJ Zacharek, E Zudaire, W Huang, DM Bonal, ... Cancer immunology research 7 (9), 1457-1471, 2019 | 117 | 2019 |
| The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma D Agdashian, M ElGindi, C Xie, M Sandhu, D Pratt, DE Kleiner, WD Figg, ... Cancer Immunology, Immunotherapy 68, 599-608, 2019 | 112 | 2019 |
| Fibrin-based 3D matrices induce angiogenic behavior of adipose-derived stem cells E Chung, JA Rytlewski, AG Merchant, KS Dhada, EW Lewis, LJ Suggs Acta biomaterialia 17, 78-88, 2015 | 91 | 2015 |
| CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with … AY Lai, JA Sorrentino, KH Dragnev, JM Weiss, TK Owonikoko, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 67 | 2020 |
| Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire A Tarhini, Y Lin, H Lin, Z Rahman, P Vallabhaneni, P Mendiratta, ... Journal for immunotherapy of cancer 6, 1-10, 2018 | 57 | 2018 |
| Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood J Rytlewski, S Deng, T Xie, C Davis, H Robins, E Yusko, J Bienkowska PLoS One 14 (3), e0213684, 2019 | 41 | 2019 |
| Rapid undetectable MRD (uMRD) responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with lisocabtagene … T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, ... Blood 134, 503, 2019 | 37 | 2019 |
| Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence W Pruessmann, J Rytlewski, J Wilmott, MC Mihm Jr, GH Attrill, ... Nature cancer 1 (2), 197-209, 2020 | 34 | 2020 |
| The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients A Khunger, JA Rytlewski, P Fields, EC Yusko, AA Tarhini Oncoimmunology 8 (11), e1652538, 2019 | 26 | 2019 |
| CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes BA Schroeder, NA LaFranzo, BJ LaFleur, RM Gittelman, M Vignali, ... Journal for immunotherapy of cancer 9 (8), 2021 | 23 | 2021 |
| Mechanisms of tubulogenesis and endothelial phenotype expression by MSCs JA Rytlewski, MA Aldon, EW Lewis, LJ Suggs Microvascular research 99, 26-35, 2015 | 22 | 2015 |
| Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial Y Lin, NS Raje, JG Berdeja, DS Siegel, S Jagannath, D Madduri, ... Nature Medicine 29 (9), 2286-2294, 2023 | 21 | 2023 |
| Three-dimensional image quantification as a new morphometry method for tissue engineering JA Rytlewski, LR Geuss, CI Anyaeji, EW Lewis, LJ Suggs Tissue Engineering Part C: Methods 18 (7), 507-516, 2012 | 17 | 2012 |
| Impact of HLA type, age and chronic viral infection on peripheral T-cell receptor sharing between unrelated individuals SA Johnson, SL Seale, RM Gittelman, JA Rytlewski, HS Robins, PA Fields PLoS One 16 (8), e0249484, 2021 | 12 | 2021 |
Krishnendu RoyGeorgia Institute of TechnologyVerified email at gatech.edu
